FREMONT, CA, March 26, 2020 – Bionova Scientific, a biologics CDMO with deep protein production, cell line development, process development and analytical expertise, today introduced a COVID-19 support program, making lab capacity available to industry partners impacted by COVID-19 shutdowns. Organizations developing COVID-19 related treatments will be given priority access through the program.
“We recognize that the capacity of the industry we serve has been severely impacted by this crisis. Meanwhile, the development timelines for new therapeutics remain as urgent as ever,” commented Bionova CEO Amy Kong. “This has coincided with an expansion of our lab capacity for the development and production of mAbs and recombinant proteins, so we want to let potential partners know that our critical lab functions are fully operational and available to keep their programs on track.”
Bionova Vice President of Business Development, Bruce Frazier, added, “We have a team and facility that deliver the highest quality CDMO services, as demonstrated by our customer loyalty here in the Bay Area. We are hoping we can act as a relief valve for companies that are struggling to find capable resources for their critical projects during this challenging time.”